Cytokinetics, Royalty Pharma expand collaboration to support commercial launch of aficamten and to advance R&D pipeline
Cytokinetics, Inc, a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating …